Quick Answer
DNA X, Inc. reported Common Stock Shares Outstanding of 4.98 million shares for the year ending 2024.
- DNA X, Inc. showed an increase of +12.6% in Common Stock Shares Outstanding from 2023 to 2024.
- This data is from DNA X, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: 15.87 million shares | Q2 2019: 20.34 million shares | Q3 2019: 20.36 million shares | Q1 2020: 20.68 million shares | Q2 2020: 65.93 million shares | Q3 2020: 66.01 million shares | Q1 2021: 66.32 million shares | Q2 2021: 66.95 million shares | Q3 2021: 9.25 million shares | Q1 2022: 19.27 million shares | Q2 2022: 19.34 million shares | Q3 2022: 40.64 million shares | Q1 2023: 41.00 million shares | Q2 2023: 41.11 million shares | Q3 2023: 42.55 million shares | Q1 2024: 43.21 million shares | Q2 2024: 4.83 million shares | Q3 2024: 4.87 million shares | Q4 2024: 276,881 shares | Q1 2025: 6.33 million shares | Q2 2025: 10.34 million shares | Q3 2025: 1.02 million shares.
- Over the full 7 years of available data (2018 to 2024), DNA X, Inc.'s Common Stock Shares Outstanding has declined by 68.0%.
- Historical annual values: Fiscal year 2024: 4.98 million shares | Fiscal year 2023: 4.43 million shares | Fiscal year 2022: 40.77 million shares | Fiscal year 2021: 18.81 million shares | Fiscal year 2020: 6.63 million shares | Fiscal year 2019: 20.44 million shares | Fiscal year 2018: 15.59 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: